4.2 Review

Metastatic Uveal Melanoma Biology and Emerging Treatments

期刊

CANCER JOURNAL
卷 18, 期 2, 页码 148-152

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/PPO.0b013e31824bd256

关键词

Uveal melanoma; GNAQ; GNA11; BAP1

类别

资金

  1. National Cancer Institute [P50CA093459]
  2. National Institutes of Health [K12CA088084]
  3. GlaxoSmithKline
  4. Bristol Myers Squibb

向作者/读者索取更多资源

Uveal melanoma is the most common primary intraocular cancer in adults. Nearly half of primary uveal melanoma tumors metastasize, but there are currently no effective therapies for metastatic uveal melanoma. The recent discovery of mutations that underlie uveal melanoma metastasis, growth, and survival provide a key to the molecular understanding of this disease. Much work is now underway to leverage this knowledge to develop effective therapies. This review summarizes recently discovered molecular features of uveal melanoma and therapies being explored to capitalize on this knowledge.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据